- Home
- ANAB
ANAB
AnaptysBio Inc.
as 11-06-2025 3:53pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.0B | IPO Year: | 2017 |
| Target Price: | $63.30 | AVG Volume (30 days): | 364.4K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.21 - $40.96 | Next Earning Date: | 11-04-2025 |
| Revenue: | $169,467,000 | Revenue Growth: | 196.42% |
| Revenue Growth (this year): | 37.52% | Revenue Growth (next year): | -8.09% |
Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | ANAB | CHIEF LEGAL OFFICER | Sep 30 '25 | Sell | $29.00 | 8,240 | $238,960.00 | 9,088 |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?
GlobeNewswire
9 days ago
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
Zacks
10 days ago
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MT Newswires
23 days ago
Wedbush Raises Price Target on AnaptysBio to $70 From $45, Keeps Outperform Rating
GlobeNewswire
25 days ago
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
MT Newswires
25 days ago
Barclays Initiates AnaptysBio at Overweight With $78 Price Target
MT Newswires
5 months ago
Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT Newswires
5 months ago
HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target
Compare ANAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.